Advertisement
Advertisement
U.S. Markets close in 4 hrs 6 mins
Advertisement
Advertisement
Advertisement
Advertisement

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9150-0.0150 (-0.78%)
As of 11:52AM EDT. Market open.
Advertisement
Sign in to post a message.
  • p
    pickhunter
    (ACOGF) MC $45 m ..Blockbuster Alzheimer Drug with Phase 3 results coming THIS quarter = 1000% opp
    https://www.alphacognition.com/_resources/images/our-pipeline-fig1c.jpg?v=0.492

    ##
  • L
    Lutz
    Opinions about the 150 million shelf?
  • P
    Poutine
    Why no volume with such good new ?
    Bullish
  • B
    Billy
    to my fellow long time posters, so sorry for bad news today, feel as if we got duped, staying in, not giving it away for pennies, good luck to you all in your future trades, my trading days are done, too many losses, too much stress, too much deceit
  • L
    Lou
    TODAY, 05/10/2018---NEEDHAM COVERS WITH A BUY AND AN $8.00 TARGET +300% UPSIDE
    THE LISBON JUNE 10-14 CONFERENCE TCON WILL PUT OUT POSITIVE RESULTS ON 102 CONFIRMED BY THE CEO
    THIS IS THE START OF THE MOVE UP.....TIME TO BUY IN AND STAY
  • J
    J0E
    De122 opens tcon up to $145 million in milestone payments and 200-300million a year profits from peak sales at Santen once commercialized... we have that opportunity from a $15 million dollar company... and don’t forget we also have a possible double or triple in value over night if j&j opt in... from the 45 million dollar payment tcon would receive they also can have 137.5 million in milestones from it and low royalties... so in the next 3-6 months a lot of upside
  • J
    J0E
    https://clinicaltrials.gov/ct2/show/NCT03211234?term=DE-122
    Estimated Study Completion Date :
    January 2020
  • A
    Alex
    De122 data is supposed to be coming out soon too this could be a big month for TCON... in addition to the 3 conferences we have DE122 data and Angio data... this is the event I have been waiting for for 3 years...
  • i
    ivar
    SAN DIEGO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, announced today that it has signed a collaborative partnership agreement with 3D Medicines (Beijing) Co., Ltd., a China-based biopharmaceutical company focused on cancer precision medical treatment, and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of Alphamab Oncology (HKEX: 9966) and a China-based clinical stage biopharmaceutical company primarily engaging in research and development, manufacturing and commercialization of biologics of oncology, for the development of envafolimab, also known as KN035, a PD-L1 single-domain antibody administered by subcutaneous injection, for development in soft tissue sarcoma in North America.

    TRACON and 3D Medicines and Jiangsu Alphamab entered into a product development collaboration whereby TRACON will be responsible for the clinical development and commercialization of envafolimab in soft tissue sarcoma in North America, with the majority of the development activities expected to occur in the U.S. TRACON will bear the costs of clinical trials and 3D Medicines and Jiangsu Alphamab will supply envafolimab at pre-negotiated prices.

    TRACON will be responsible for commercializing envafolimab for sarcoma in North America, except in certain circumstances involving the approval of envafolimab for other indications in North America, in which case TRACON has the option to co-market envafolimab for sarcoma in North America.

    If TRACON has responsibility for commercialization under the Collaboration Agreement, it will owe 3D Medicines and Jiangsu Alphamab escalating double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits, which amounts shall be split between 3D Medicines and Jiangsu Alphamab as negotiated. If 3D Medicines and Jiangsu Alphamab have responsibility for commercialization under the Collaboration Agreement, TRACON will be entitled to (a) escalating double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits if TRACON has chosen to not co-market envafolimab in sarcoma or (b) a 50% royalty on net sales of envafolimab for sarcoma in North America if TRACON has chosen to co-market envafolimab in sarcoma.
    Bullish
  • L
    Lutz
    Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) in Each Cohort Satisfied the Bar for Futility and Supports Continued Accrual.

    meets the bar = 11%????
  • B
    Billy
    de122 study discontinued, wow what a surprise, glad I didn't get filled today at 1.98, will buy at a buck tomorrow, what a joke this company is, Sorry Guys to be the bearer of bad news, but I should of known better
  • A
    Alex
    huge volume to start the day... did it's entire daily average in first 20 mins... what is up is there a note released or something?
  • V
    VisionaryAbove
    Well first things first, just wanted to say get ready for this board to get extremely crowded as thisncontinues higher into data cuts. Good luck gang and stay intouch...

    Second this was walked back down on AIR this afternoon. Someone clearly accumulating shares before this starts to get away from all of us it seems. I’m setting limit orders North of $10, no borrows on my shares that’s for sure.

    VA
  • A
    Alex
    8 of the 12 patients in the DE122 trial experienced bioactivity...
  • B
    Billy
    any reason to be optimistic
  • J
    J0E
    One thing no one talks about is the possibility that tcon has to pay jnj and jassen

    “ If Janssen opts not to exercise that option, Tracon said, it would retain worldwide development and commercialization rights to the program and would have to pay Janssen up to $45 million in development and regulatory milestone payments plus a low-single-digit royalty.“
  • G
    G.S
    Bought 2,000 shares at $2.90 this morning, premarket. Thought it would run a little. Never seen something go from 30% gain to hitting its 52 week low. Guess I will be holding for awhile now.
  • T
    Tartiaboy
    I will continue to watch TCON. I don't think the story is over. Many irons in the fire. Need to see where things stand once the dust settles.

    I think anti-endoglin can still find a role in oncology, but it will take more time.
  • B
    Billy
    @Alex..after the recent trial failures, the earlier delay in angioplasty trial, and the Ambrx bailout, what gives you confidence in this company?
  • B
    Billy
    why the volume?
Advertisement
Advertisement